IGEN International Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International

IGEN 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Perry who wrote (281)	3/7/1998 4:19:00 PM
From: John Zwiener	Read Replies (1) of 1025

I think you are asking 2 questions. One question implied in your message is how is the ability to create a new immunoassay test in such a short time a big advantage? In pursuing a new drug, tests are done that create reactions and substances. In many cases, you are looking for a drug that results in an effect that causes changes in some target substance. Speeding up the ability to quickly weave this way or that to check so incidental finding can over time save vital months or years, particularily in a "hot" area where there are competators. The other question as to how they do it so fast, well I"m not sure. I think it has to do with the Origen platform. Because of the ease of attachment of the antibody or antisense molecule to the signal and due to lack of interference from background noise, it's not necessary to fine tune the test to make it accurate.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next